132 related articles for article (PubMed ID: 9781003)
1. The role of fluorodeoxyglucose and positron emission tomography in the evaluation of pancreatic disease.
Rajput A; Stellato TA; Faulhaber PF; Vesselle HJ; Miraldi F
Surgery; 1998 Oct; 124(4):793-7; discussion 797-8. PubMed ID: 9781003
[TBL] [Abstract][Full Text] [Related]
2. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
3. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer.
Imdahl A; Nitzsche E; Krautmann F; Högerle S; Boos S; Einert A; Sontheimer J; Farthmann EH
Br J Surg; 1999 Feb; 86(2):194-9. PubMed ID: 10100786
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of pancreatic carcinoma: role of FDG PET.
Keogan MT; Tyler D; Clark L; Branch MS; McDermott VG; DeLong DM; Coleman RE
AJR Am J Roentgenol; 1998 Dec; 171(6):1565-70. PubMed ID: 9843289
[TBL] [Abstract][Full Text] [Related]
6. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
7. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
8. 18-Fluorodeoxyglucose positron emission tomography does not aid in diagnosis of pancreatic ductal adenocarcinoma.
Matsumoto I; Shirakawa S; Shinzeki M; Asari S; Goto T; Ajiki T; Fukumoto T; Kitajima K; Ku Y
Clin Gastroenterol Hepatol; 2013 Jun; 11(6):712-8. PubMed ID: 23353642
[TBL] [Abstract][Full Text] [Related]
9. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
10. The possible role of F-18 FDG positron emission tomography in the differential diagnosis of focal pancreatic lesions.
Papós M; Takács T; Trón L; Farkas G; Ambrus E; Szakáll S; Lonovics J; Csernay L; Pávics L
Clin Nucl Med; 2002 Mar; 27(3):197-201. PubMed ID: 11852308
[TBL] [Abstract][Full Text] [Related]
11. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.
Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN
Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750
[TBL] [Abstract][Full Text] [Related]
12. Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses.
Diederichs CG; Staib L; Vogel J; Glasbrenner B; Glatting G; Brambs HJ; Beger HG; Reske SN
Pancreas; 2000 Mar; 20(2):109-16. PubMed ID: 10707924
[TBL] [Abstract][Full Text] [Related]
13. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma.
Mertz HR; Sechopoulos P; Delbeke D; Leach SD
Gastrointest Endosc; 2000 Sep; 52(3):367-71. PubMed ID: 10968852
[TBL] [Abstract][Full Text] [Related]
14. [Fluorodeoxyglucose positron emission tomography (FDG-PET) in the differential diagnosis of pancreatic lesions].
Zimny M; Schumpelick V
Chirurg; 2001 Sep; 72(9):989-94. PubMed ID: 11594284
[TBL] [Abstract][Full Text] [Related]
15. Differential diagnosis of benign and malign pancreatic masses with 18F-fluordeoxyglucose-positron emission tomography recorded with a dual-head coincidence gamma camera.
Singer E; Gschwantler M; Plattner D; Kriwanek S; Armbruster C; Schueller J; Feichtinger H; Roka R; Moeschl P; Weiss W; Kroiss A
Eur J Gastroenterol Hepatol; 2007 Jun; 19(6):471-8. PubMed ID: 17489057
[TBL] [Abstract][Full Text] [Related]
16. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations.
Sendler A; Avril N; Helmberger H; Stollfuss J; Weber W; Bengel F; Schwaiger M; Roder JD; Siewert JR
World J Surg; 2000 Sep; 24(9):1121-9. PubMed ID: 11036292
[TBL] [Abstract][Full Text] [Related]
17. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.
Bares R; Klever P; Hauptmann S; Hellwig D; Fass J; Cremerius U; Schumpelick V; Mittermayer C; Büll U
Radiology; 1994 Jul; 192(1):79-86. PubMed ID: 8208970
[TBL] [Abstract][Full Text] [Related]
18. [The value of fluorodeoxyglucose positron emission tomography (FDG-PET) in differentiation of pancreatic lesions].
Voth M; Opfermann T; Gottschild D
Zentralbl Chir; 2003 May; 128(5):375-8. PubMed ID: 12813634
[TBL] [Abstract][Full Text] [Related]
19. [18FDG-PET imaging of pancreatic adenocarcinoma].
Daenen F; Hustinx R; Belhocine T; Focan C; Honoré P; Rigo P
Rev Med Liege; 2000 Feb; 55(2):89-94. PubMed ID: 10769575
[TBL] [Abstract][Full Text] [Related]
20. [The role of FDG-PET scan in the diagnosis of pancreatic carcinoma].
Papós M; Takács T; Pávics L; Farkas G; Ambrus E; Szakáll S; Lonovics J; Csernay L; Trón L
Orv Hetil; 2002 May; 143(21 Suppl 3):1283-6. PubMed ID: 12077917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]